Cancer Metastasis, Epithelial-Mesenchymal Transition, Lineage Plasticity, Acquired Resistance to Cancer Therapeutics, Beta Adrenergic Signaling in Tumor Progression, Angiogenesis, Patient Derived Xenograft Models, Cancer Molecular Diagnosis
Cancer metastasis, the spread of tumor to other parts of patient's body, is responsible for over 90% of cancer death. However, it is still poorly understood and the current approaches to prevent or treat human metastatic diseases are mostly unsuccessful. Through genomics, RNAi and cDNA functional screens, Dr. Li's lab has identified several critical but previously unknown regulators for cancer metastasis. Signaling pathways and molecular mechanisms of these genes are in study with molecular, cellular, biochemical, genomic and proteomic approaches, as well as with mouse models and patient samples. For example, Dr. Li's lab is studying GRK3 (G-protein coupled receptor kinase 3), a kinase they identified from functional screens, in the progression of CRPC (castration resistant prostate cancer), especially the highly metastatic variant of CRPC, the t-NEPC (treatment-related neuroendocrine prostate cancer). These studies will yield new insights in cancer metastasis and facilitate the development of new cancer therapeutics and biomarkers.
Publications/Creative Works
Click here to search for this faculty member's publications on PubMed.
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.